![]() |
ISSUER FREE WRITING PROSPECTUS
|
Filed Pursuant to Rule 433
|
|
Registration Statement No. 333-283969
|
|
Dated April 4, 2025
|
SUMMARY TERMS
|
||
Issuer:
|
The Toronto-Dominion Bank
|
|
Issue:
|
Debt Securities, Series H
|
|
Underlying stock:
|
Common Stock of Wells Fargo & Company (Bloomberg Ticker: “WFC UN”)
|
|
Stated principal amount:
|
$1,000.00 per security
|
|
Minimum investment:
|
$1,000 (1 security)
|
|
Pricing date:
|
April 11, 2025
|
|
Original issue date:
|
April 16, 2025 (3 business days after the pricing date; see preliminary pricing supplement).
|
|
Final determination date:
|
April 11, 2028, subject to postponement for certain market disruption events and as described in the accompanying product
supplement.
|
|
Maturity date:
|
April 17, 2028, subject to postponement for certain market disruption events and as described in the accompanying product
supplement.
|
|
Early redemption:
|
If the closing price of the underlying stock on any determination date other than the final determination date is greater than or equal to the call threshold price, the securities will be automatically redeemed for an amount per security equal to the early redemption payment on the first contingent coupon payment
date immediately following the related determination date. No further payments will be made on the securities once they have been redeemed.
|
|
Early redemption
payment:
|
The early redemption payment will be an amount equal to (i) the stated principal amount plus (ii) the contingent quarterly
coupon with respect to the applicable determination date.
|
|
Contingent quarterly
coupon:
|
■
|
If the closing price on any determination date is greater than or equal to the
downside threshold price, we will pay a contingent quarterly coupon of $26.25 (equivalent to 10.50% per annum of the stated principal amount) per security on the related contingent coupon payment date.
|
■
|
If the closing price on any determination date is less than the downside threshold
price, we will not pay a contingent quarterly coupon with respect to that determination date.
|
|
Determination dates:
|
Quarterly (as set forth on the cover of the preliminary pricing supplement), subject to postponement for non-trading days and
certain market disruption events as described in the accompanying product supplement
|
|
Contingent coupon
payment dates:
|
Quarterly (as set forth on the cover of the preliminary pricing supplement), subject to postponement for non-business days and
certain market disruption events as described in the accompanying product supplement
|
|
Payment at maturity:
|
■
|
If the final share price is greater than or equal to the downside threshold price:
(i) the stated principal amount plus (ii) the contingent quarterly coupon with
respect to the final determination date
|
■
|
If the final share price is less than the downside threshold price:
(i) the stated principal amount multiplied by (ii) the share performance factor
If the final share price is less than the downside threshold price, the payment at maturity will be less
than 65% of the stated principal amount and could be as low as zero.
|
|
Share performance
factor:
|
Final share price divided by the initial share price
|
|
Call threshold price:
|
100% of the initial share price, as may be adjusted in the case of certain adjustment events as described in the accompanying
product supplement
|
|
Downside threshold
price:
|
65% of the initial share price, as may be adjusted in the case of certain adjustment events as described in the accompanying
product supplement
|
|
Initial share price:
|
The closing price of the underlying stock on the pricing date, as may be adjusted in the case of certain adjustment events as
described in the accompanying product supplement
|
|
Final share price:
|
The closing price of the underlying stock on the final determination date, as may be adjusted in the case of certain adjustment
events as described in the accompanying product supplement
|
|
CUSIP / ISIN:
|
89115HB22 / US89115HB227
|
|
Listing:
|
The securities will not be listed or displayed on any securities exchange or any electronic communications network.
|
|
Commission:
|
$22.50 per stated principal amount
|
|
Estimated value on the
pricing date:
|
Expected to be between $925.00 and $960.00 per security. See “Risk Factors” in the preliminary pricing supplement.
|
|
Preliminary pricing
supplement:
|
HYPOTHETICAL PAYOUT
|
Change in Underlying Stock
|
Payment at Maturity (excluding any
contingent quarterly coupon
payable at maturity)
|
+50.00%
|
$1,000.00
|
+40.00%
|
$1,000.00
|
+30.00%
|
$1,000.00
|
+20.00%
|
$1,000.00
|
+10.00%
|
$1,000.00
|
0.00%
|
$1,000.00
|
-10.00%
|
$1,000.00
|
-20.00%
|
$1,000.00
|
-30.00%
|
$1,000.00
|
-35.00%
|
$1,000.00
|
-36.00%
|
$640.00
|
-40.00%
|
$600.00
|
-50.00%
|
$500.00
|
-60.00%
|
$400.00
|
-70.00%
|
$300.00
|
-80.00%
|
$200.00
|
-90.00%
|
$100.00
|
-100.00%
|
$0.00
|
|
▪ |
Risk of loss at maturity.
|
▪ |
Contingent repayment of stated principal amount only at maturity.
|
▪ |
You may not receive any contingent quarterly coupons.
|
▪ |
Greater expected volatility with respect to the underlying stock generally reflects a higher contingent quarterly coupon and a higher expectation as of the pricing date that the final share price of the underlying
stock could be less than the downside threshold price on the final determination date.
|
▪ |
The securities are subject to reinvestment risk in the event of an early redemption.
|
▪ |
The contingent quarterly coupon, if any, is based solely on the closing price or the final share price, as applicable.
|
▪ |
Your potential return on the securities is limited, you will not participate in any appreciation of the underlying stock and you will not realize a return beyond the returns represented by the contingent quarterly
coupons received, if any, during the term of the securities.
|
▪ |
The securities are subject to risks associated with investments in single equity securities.
|
▪ |
There can be no assurance that the investment view implicit in the securities will be successful.
|
▪ |
There is no affiliation between TD and the underlying stock issuer.
|
▪ |
The estimated value of your securities is expected to be less than the public offering price of your securities.
|
▪ |
The estimated value of your securities is based on our internal funding rate.
|
▪ |
The estimated value of the securities is based on our internal pricing models, which may prove to be inaccurate and may be different from the pricing models of other financial institutions.
|
▪ |
The estimated value of your securities is not a prediction of the prices at which you may sell your securities in the secondary market, if any, and such secondary market prices, if any, will likely be less than the
public offering price of your securities and may be less than the estimated value of your securities.
|
▪ |
The temporary price at which the agent may initially buy the securities in the secondary market may not be indicative of future prices of your securities.
|
▪ |
The underwriting discount, offering expenses and certain hedging costs are likely to adversely affect secondary market prices.
|
▪ |
There may not be an active trading market for the securities — sales in the secondary market may result in significant losses.
|
▪ |
If the price of the underlying stock changes, the market value of your securities may not change in the same manner.
|
▪ |
Investors are subject to TD’s credit risk, and TD’s credit ratings and credit spreads may adversely affect the market value of the securities.
|
▪ |
There are potential conflicts of interest between you and the calculation agent.
|
▪ |
The calculation agent can make antidilution and other adjustments that may adversely affect the market value of, and any amounts payable on, the securities.
|
▪ |
Trading and business activities by TD or its affiliates may adversely affect the market value of, and any amounts payable on, the securities.
|
▪ |
The calculation agent will have significant discretion with respect to the securities, which may be exercised in a manner that is adverse to your interests.
|
▪ |
Significant aspects of the tax treatment of the securities are uncertain.
|